Company intelligence / Profile preview
Clarity Pharmaceuticals
Sydney, New South Wales, Australiaclaritypharmaceuticals.com ↗
- Ownership
- Public · CU6
- Employees
- ~50
- Development stage
- Other
01
Overview
Clarity is developing next-generation radiopharmaceutical products using their proprietary SAR Technology platform. Their lead product SAR-bisPSMA is in clinical development, along with SAR-Bombesin (in Phase II SABRE trial for prostate cancer) and SARTATE (in trials for neuroblastoma and neuroendocrine tumors).
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsTheranostics
- Industry
- Biotech
02
Drug pipeline
25 assets24 more assets in the full pipeline.
03
Financials
- Market cap
- $383.5M
- Total revenue
- $0
- Enterprise value
- $261M
Beyond the preview
Go deeper on Clarity Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clarity Pharmaceuticals.